The revenues for February ($4.4M) are nice but it's only half the story. The bigger half of the story is that ScripsAmerica has moved away from bring a one product/service company to a company with 3 defined revenue streams with a $53M annual run rate. Diabetes and PIMD are in their infancy stage and the impact on future revenues with these two streams can add significantly to the bottom line. There isn't a penny stock anywhere with business fundamentals as strong as SCRC's.